Paper42657191
Graphene and Graphene Oxide-Based Nanocarriers for Targeted Delivery of Mitoxantrone in Cancer Therapy.
Talebi Haftadori Z and 3 others. Int J Nanomedicine, 2026. Cited by 0 papers, by iCite.
Cite this record
ConductScience Library. Graphene and Graphene Oxide-Based Nanocarriers for Targeted Delivery of Mitoxantrone in Cancer Therapy. Papers, record 42657191. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/42657191
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- Graphene and Graphene Oxide-Based Nanocarriers for Targeted Delivery of Mitoxantrone in Cancer Therapy.
- PubMed
Topics8
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Graphite | Major topic |
| Mitoxantrone | Major topic |
| Neoplasms | Major topic |
| Antineoplastic Agents | Major topic |
| Drug Carriers | Major topic |
| Humans | |
| Animals | |
| Drug Delivery Systems |
Source PubMed
References38
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 31355696 | A smart drug-delivery nanosystem based on carboxylated graphene quantum dots for tumor-targeted chemotherapy. | Nanomedicine (Lond) | 2019 | https://conductscience.org/library/papers/31355696 | PubMed |
| 2 | 38745193 | Magnetically modified-mitoxantrone mesoporous organosilica drugs: an emergent multimodal nanochemotherapy for breast cancer. | J Nanobiotechnology | 2024 | https://conductscience.org/library/papers/38745193 | PubMed |
| 3 | 34866166 | Nanoparticles for Cancer Therapy: Current Progress and Challenges. | Nanoscale Res Lett | 2021 | https://conductscience.org/library/papers/34866166 | PubMed |
| 4 | 36883982 | Graphene family in cancer therapy: recent progress in cancer gene/drug delivery applications. | J Mater Chem B | 2023 | https://conductscience.org/library/papers/36883982 | PubMed |
| 5 | 32992117 | Photo-activated chemo-immunotherapy for metastatic cancer using a synergistic graphene nanosystem. | Biomaterials | 2021 | https://conductscience.org/library/papers/32992117 | PubMed |
| 6 | 27547843 | Nanodrug Delivery: Is the Enhanced Permeability and Retention Effect Sufficient for Curing Cancer? | Bioconjug Chem | 2016 | https://conductscience.org/library/papers/27547843 | PubMed |
| 7 | 38529035 | Disease-modifying therapy in progressive multiple sclerosis: a systematic review and network meta-analysis of randomized controlled trials. | Front Neurol | 2024 | https://conductscience.org/library/papers/38529035 | PubMed |
| 8 | 29928344 | Mitoxantrone induces apoptosis in osteosarcoma cells through regulation of the Akt/FOXO3 pathway. | Oncol Lett | 2018 | https://conductscience.org/library/papers/29928344 | PubMed |
| 9 | 3521429 | Mitoxantrone: a new anticancer drug with significant clinical activity. | Ann Intern Med | 1986 | https://conductscience.org/library/papers/3521429 | PubMed |
| 10 | 38572751 | Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. | CA Cancer J Clin | 2024 | https://conductscience.org/library/papers/38572751 | PubMed |
| 11 | 40563442 | Biological Nanocarriers in Cancer Therapy: Cutting Edge Innovations in Precision Drug Delivery. | Biomolecules | 2025 | https://conductscience.org/library/papers/40563442 | PubMed |
| 12 | 26286294 | Mitoxantrone, More than Just Another Topoisomerase II Poison. | Med Res Rev | 2016 | https://conductscience.org/library/papers/26286294 | PubMed |
| 13 | 35965519 | Cancer chemotherapy: insights into cellular and tumor microenvironmental mechanisms of action. | Front Oncol | 2022 | https://conductscience.org/library/papers/35965519 | PubMed |
| 14 | 33370092 | Chemo-physical Strategies to Advance the in Vivo Functionality of Targeted Nanomedicine: The Next Generation. | J Am Chem Soc | 2021 | https://conductscience.org/library/papers/33370092 | PubMed |
| 15 | 37566091 | Biogenic Silver Nanoparticles for Targeted Cancer Therapy and Enhancing Photodynamic Therapy. | Cells | 2023 | https://conductscience.org/library/papers/37566091 | PubMed |
| 16 | 35008083 | Construction of an exosome-functionalized graphene oxide based composite bionic smart drug delivery system and its anticancer activity. | Nanotechnology | 2022 | https://conductscience.org/library/papers/35008083 | PubMed |
| 17 | 28883419 | Bio-fabrication of silver nanoparticles by phycocyanin, characterization, in vitro anticancer activity against breast cancer cell line and in vivo cytotxicity. | Sci Rep | 2017 | https://conductscience.org/library/papers/28883419 | PubMed |
| 18 | 41174009 | Steric stabilization-independent stealth cloak enables nanoreactors-mediated starvation therapy against refractory cancer. | Nat Biomed Eng | 2026 | https://conductscience.org/library/papers/41174009 | PubMed |
| 19 | 39370518 | Biomimetic nanocarriers in cancer therapy: based on intercellular and cell-tumor microenvironment communication. | J Nanobiotechnology | 2024 | https://conductscience.org/library/papers/39370518 | PubMed |
| 20 | 29457592 | PEGylated graphene oxide/Fe3O4 nanocomposite: Synthesis, characterization, and evaluation of its performance as de novo drug delivery nanosystem. | Biomed Mater Eng | 2018 | https://conductscience.org/library/papers/29457592 | PubMed |
Genes2
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
| Gene | NCBI Gene ID | Linked by | In Genes | Source |
|---|---|---|---|---|
| ABCB1 | 5243 | PubTator's text mining | https://conductscience.org/library/genes/5243 | NCBI Gene |
| CD44 | 960 | PubTator's text mining | https://conductscience.org/library/genes/960 | NCBI Gene |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- Cited by
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/42657191
GET https://conductscience.org/api/papers/v1/42657191/references?page=2